Anti-Infectives Partnering & Deal-Making Summit

8:00 Building on Successes: Merck's Approach to Anti-infective Partnering
Sundeep Lal, Ph.D., MBA, Senior Director, External Scientific Affairs, Merck & Co.

8:30 TBD
Gilead

9:00 It’s Not About the Target
David Pompliano, Vice President, Biology, MMPD CEDD, GlaxoSmithKline

9:30 Refreshment Break

10:00 PANEL: Recent Partnering and Interest in Antibiotics
Chair: Dennis Molnar, Executive Director, Corporate Development, Paratek Pharmaceuticals

Praveen Tipirneni, Senior Director, Corporate Development, Cubist Pharmaceuticals
Sundeep Lal, Ph.D., MBA, Senior Director, External Scientific Affairs, Merck & Co.
Yujiro Hata, VP Business Development, Enanta Pharmaceuticals

Session II: Antibiotics/Antifungals

10:45 Review of Global Antibiotic/Antifungal Pipelines
Praveen Tipirneni, Senior Director, Corporate Development, Cubist Pharmaceuticals

11:15 Anti-Infective Biologics: A 'Humaneered' Anti-Pseudomonas Antibody
Mark Alfenito, President, KaloBios Pharmaceuticals

11:45 The Commercialization Story of Factive and Oscient - The Sequel
Glenn Tillotson, VP, Scientific & Medical Relations, Oscient Pharmaceuticals

12:15 Pipeline Building in an Era of Market Segmentation Driven by Drug Resistance
Kevin Eastwood, Senior Vice President, Business Development, Achillion Pharmaceuticals

12:45 Lunch

1:45 PANEL: Investment Opportunities in the Anti-Infectives Space
Chair: Jeff Stein, Partner, San Diego, Sofinnova Ventures

Doug Wall, Partner, Venture Advisors
John North, President & CEO, Inimex
Eckard Weber, M.D., Venture Partner, Domain Associates
Camille Samuels, Managing Director, Versant Ventures
Jeanne Cunicelli, Partner, Bay City Capital

SESSION III: Valuation and Business Models

2:45 Valuation of Compounds: What does it mean- comparing Anti-Infectives
Michael McCully, Director, Recombinant Capital

3:15 The European Biotech Model – Consolidation or Disappointment?
Ursula Theuretzbacher, Center for Anti-Infective Agents, Europe

3:45 Refreshment Break

SESSION IV: IP and Regulatory

4:15 Developing Pricing & Reimbursement Strategies for Antiinfectives
Volker Janssen, Partner, Simon-Kucher & Partners

4:45 Opportunities to Partner w/ the Division of Microbiology & Infectious Diseases Resources
Katherine Taylor, Therapeutics Development Program Officer, NIAID, NIH

5:15 Update on Patent Law and Its Impact on Life Sciences Inventions
Lisa Haile, Ph.D., J.D., Partner, DLA Piper

5:45 Networking Reception/Poster Viewing


Day 2: Friday, January 27, 2006

7:15 Registration & Breakfast

8:00 KEYNOTE ADDRESS
From a Biotech to a Biopharmaceutical Company: The Replidyne Story
Ken Collins, President & CEO, Replydine, Inc.

SESSION V: AntiVirals

8:45 Where are the future areas of growth in infectious diseases, 2006?
John Lebbos, M.D., Infectious Diseases Director, Decision Resources, Inc.

9:15 Development of HCV Anti-Viral Therapies: A Partnering Perspective from InterMune
Tom Kassberg, SVP, Business Development & Corporate Strategy, InterMune Pharmaceuticals

9:45 Refreshment Break

10:15 Trends in Prophylactic Vaccines
Clement Lewin, Vice President US Govt. Affairs & Strategy, Acambis

10:45 NexBio: Leading the Quest for the Ultimate Influenza Medicine
Mang Yu, President & CEO, NexBio, Inc.

11:15 PANEL: Bird Flu Pandemic

Mang Yu, President & CEO, NexBio, Inc.
Invited: Mark Armitage, Chiron Vaccines
Invited: Michel Baijot, GSK
Invited: Jonathan Klein-Evans, MedImmune

12:00 Lunch

SESSION VI: Diagnostics & Drug Discovery Approaches

1:00 Molecular Diagnostics meet Therapeutics
Henrik Stender, VP, Research and Development, AdvanDx

1:20 Building Partnering Value through Targeted Antibiotic Discovery and Development
Graham Johnson, Chief Research Officer, Rib-X Pharmaceuticals

1:40 Targeted Anti-Infectives for Treatment of Drug Resistant Infections
Elizabeth Posillico, President & CEO, Elusys Therapeutics, Inc.

2:10 Tarmogens: Immunotherapy using Recombinant Saccharomyces Cerivisiae for the Treatment of Chronic Viral Diseases
David Apelian, M.D., Ph.D., MBA, Chief Medical Officer, GlobeImmune

2:30 Broad-Spectrum Antiviral Drugs: Why not?
Paul Olivo, President & CSO, Apath, LLC

2:50 Refreshment Break

3:10 "It's a Jungle Out There": Successful Discovery of New Anti-Infectives from Plants
Victoria Gordon, CEO, EcoBiotics

3:30 The Evolving Vaccine Industry, and the Business of Biodefense
Elaine Cheung, Sr Mgr Business Development, VaxGen

3:50 Preventing Expression of Chromosomal Resistance Determinates
J. Kevin Judice, PhD, CSO, Achaogen, Inc

4:10 Oral Presentations from Selected Abstracts
Submit your abstract before Dec. 26, 2005 to be considered

4:30 Conference Concludes

Sponsorships & Exhibition Opportunities Available
Call 626-256-6405 for More Details

Tom Kassberg
SVP, Bus Development & Corporate Strategy, Intermune Pharmaceuticals

Katherine Taylor, Ph.D.
Therapeutics Development Program Officer, Office of Biodefense Research Affairs, DMID, NIAID, NIH

Glenn S. Tillotson, Ph.D., FRSM
Vice President, Scientific and Medical Relations, Oscient Pharmaceuticals

Dennis Molnar
Executive Director, Corporate Development, Paratek Pharmaceuticals

Sundeep Lal, Ph.D., MBA
Senior Director, External Scientific Affairs, Merck & Co.

Yujiro Hata
VP Business Development, Enanta Pharmaceuticals

Kevin Eastwood
Vice President, Business Development, Achillion Pharmaceuticals

Mang Yu, Ph.D.
President & CEO, NexBio, Inc.

Victoria Gordon
CEO, EcoBiotics Discovery Ltd

Elaine Cheung
Sr Mgr Business Development, VaxGen, Inc.

Eckard Weber, M.D.
Venture Partner, Domain Associates

Camille Samuels
Managing Director, Versant Ventures

Jeanne Cunicelli
Partner, Bay City Capital

Paul D. Olivo, M.D., Ph.D.
President & CSO, Apath, LLC

John Lebbos, M.D.
Infectious Diseases Director, Decision Resources, Inc.

Michael McCully
Director, Recombinant Captial

Lisa Haile, Ph.D., J.D.
Partner, DLA Piper Rudnick Gray Cary

Mark Afenito, Ph.D.
President, Kalobios

Volker Janssen, Ph.D.
Partner, Simon-Kucher & Partners

John North, Ph.D.
President & CEO, Inimex Pharmaceuticals

Henrik Stender, Ph.D.
VP, Research and Development, AdvanDx

Praveen Tipirneni
Senior Director, Corporate Development, Cubist Pharmaceuticals

Kevin Judice, Ph.D.
CSO, Achaogen, Inc

David Pompliano
Vice President & Head of Biology, GlaxoSmithKline

David Apelian
Chief Scientific Officer, GlobeImmune

Elizabeth G. Posillico, PhD
Elusys Therapeutics, Inc.

Jeff Stein, Ph.D.
Life Science Venture Partner, Sofinnova Ventures

Clement Lewin
VP, US Government Affairs & Strategy, Acambis

Douglas Wall
Partner & Managing Director, West Coast, Venture Advisors

Graham Johnson, Ph.D.
Chief Research Officer, Rib-X Pharmaceuticals, Inc.

Early registration discount

20% off if you register before Nov 26, 2006. 10% off if you register before Dec 26, 2006.